Castlight Health to Participate in Upcoming Investor Conference
Get Alerts CSLT Hot Sheet
Join SI Premium – FREE
SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Castlight Health, Inc. (NYSE: CSLT), a leading health benefits platform provider, today announced that Maeve O'Meara, chief executive officer, and Will Bondurant, chief financial officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, 2020 at 1:15pm ET. A live audio-only webcast and related presentation materials will be available on the Investor Relations section of www.castlighthealth.com.
About Castlight Health
Castlight is on a mission to make it as easy as humanly possible for its users to navigate the healthcare system and live happier, healthier, more productive lives. Our health navigation platform connects hundreds of health vendors, benefits resources, and plan designs into one comprehensive health and wellbeing experience. We guide individuals—based on their unique profile—to the best resources available to them, whether they are healthy, chronically ill, or actively seeking medical care. Castlight transforms the employee benefit experience into a deeply personalized, yet simple, guided one, empowering better-informed patient decisions to unlock better healthcare outcomes and maximizing return on healthcare investments.
For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.
Castlight Media Contact:Caroline Kawashima[email protected] 415-246-0313
Castlight Investor Contact:[email protected] 443-213-0500
View original content to download multimedia:http://www.prnewswire.com/news-releases/castlight-health-to-participate-in-upcoming-investor-conference-301161394.html
SOURCE Castlight Health, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RelaxPLX® Gains Health Canada License, and South Korean Sleep Quality Support Claim
- REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
- CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Credit Suisse, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share